FindTrial
Sign In

A real-world Study for Osimertinib in the Treatment of Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

A real-world Study for Osimertinib in the Treatment of Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019903
Enrollment
Unknown
Registered
2018-12-08
Start date
2018-12-20
Completion date
Unknown
Last updated
2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Case series:Osimertinib

Sponsors

Shanghai Chest Hospital, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed after Apr 14, 2017; 2. Non-small-cell lung cancer confirmed histologically/cytologically; 3. TNM Stage, Stage IIIb or IV (AJCC v7); 4. Patients previously treated with Osimertinib.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
PFS;TTP;OS;—

Countries

China

Contacts

Public ContactLu Shun

Shanghai Chest Hospital, Shanghai Jiaotong University

56485747@qq.com+86 13601813062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026